EP Patent

EP2452669A1 — Ophthalmic composition

Assigned to Omnivision GmbH · Expires 2012-05-16 · 14y expired

What this patent protects

The present invention relates to an aqueous ophthalmic composition comprising (i) a prostaglandin; and (ii) one or more anionic surfactants, characterized in that the concentration of anionic surfactant in the ophthalmic composition is from 0.001 to 1.0 g/L.

USPTO Abstract

The present invention relates to an aqueous ophthalmic composition comprising (i) a prostaglandin; and (ii) one or more anionic surfactants, characterized in that the concentration of anionic surfactant in the ophthalmic composition is from 0.001 to 1.0 g/L.

Drugs covered by this patent

Patent Metadata

Patent number: EP2452669A1
Jurisdiction: EP
Classification: —
Expires: 2012-05-16
Drug substance claim: No
Drug product claim: No
Assignee: Omnivision GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.